FERMENTA
Fermenta Biotech share price & financials
- Price
- ₹431.5
- Market cap
- ₹1.4k Cr
- Sector
- Healthcare
What Fermenta Biotech Limited does
Fermenta Biotech makes scientifically-validated nutritional ingredients, chiefly Vitamin D3 for human and animal nutrition, alongside pharmaceutical APIs & intermediates, enzyme-based "green chemistry" products, and biotechnology solutions for water/waste-management applications. It manufactures across dedicated plants in Kullu (Himachal Pradesh), Dahej (Gujarat) and Pennepalli (Andhra Pradesh), with its Thane (Maharashtra) site serving as corporate HQ and R&D/innovation centre, and also collaborates with a toll manufacturer in Germany for Vitamin D3 500 feed-grade powder. Its output serves pharmaceutical, dietary-supplement, food-fortification, and veterinary/animal-feed manufacturers globally.
Segments
- Nutrition
- API & Intermediates
- Green Chemistry
- Environmental
- Manufacturing & R&D sites
- 4 (Kullu, Himachal Pradesh; Dahej, Gujarat; Thane, Maharashtra – HQ+R&D; Pennepalli, Andhra Pradesh)
- Global customers
- 650+
- Countries served
- 60+
- Scientists & engineers
- 100+
- Key certifications
- 15+ (incl. WHO-GMP, USFDA, FSSC, HALAL, KOSHER, GAIN)
- Years of manufacturing expertise
- 75+
Quarterly results
Q1 FY27: revenue down 5.9%, net profit down 6.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 146 | 122 | 119 | 107 +19% | 114 −22% | 110 −10% | 112 −6% |
| EBITDA | 15 | 50 | 33 | 23 | 23 +53% | 23 −54% | 22 −33% | 23 +0% |
| Net profit | 8 | 35 | 29 | 16 | 15 +88% | 12 −66% | 22 −24% | 15 −6% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +34.9% 1Y
1Y: ₹351.85 on 10 Sept 2025 → ₹474.65. High ₹560.6 (7 Aug 2026), low ₹262.85 (29 Oct 2025).
Financials, as filed
Revenue grew 21.1% a year over 2 years, FY24 to FY26. Operating margin widened to 20.2%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹307 Cr | ₹431 Cr | ₹450 Cr |
| Operating profit | ₹36 Cr | ₹100 Cr | ₹91 Cr |
| Operating margin | 11.7% | 23.2% | 20.2% |
| Interest | ₹17 Cr | ₹14 Cr | ₹12 Cr |
| Depreciation | ₹24 Cr | ₹24 Cr | ₹21 Cr |
| Net profit | ₹-18 Cr | ₹67 Cr | ₹65 Cr |
| Net margin | -5.9% | 15.5% | 14.4% |
| Cash from operations | ₹105 Cr | ₹34 Cr | ₹83 Cr |
| Free cash flow | ₹86 Cr | ₹31 Cr | ₹52 Cr |
| ROCE | 4.0% | 20.0% | 18.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹15 Cr | ₹14 Cr |
| Reserves | ₹356 Cr | ₹382 Cr | ₹322 Cr | ₹300 Cr | ₹376 Cr | ₹408 Cr |
| Borrowings | ₹234 Cr | ₹241 Cr | ₹219 Cr | ₹139 Cr | ₹112 Cr | ₹113 Cr |
| Other liabilities | ₹78 Cr | ₹76 Cr | ₹108 Cr | ₹112 Cr | ₹149 Cr | ₹116 Cr |
| Total liabilities | ₹683 Cr | ₹713 Cr | ₹664 Cr | ₹565 Cr | ₹651 Cr | ₹652 Cr |
| Fixed assets | ₹250 Cr | ₹287 Cr | ₹257 Cr | ₹267 Cr | ₹219 Cr | ₹220 Cr |
| Capital work in progress | ₹57 Cr | ₹35 Cr | ₹45 Cr | ₹2 Cr | ₹26 Cr | ₹13 Cr |
| Investments | ₹13 Cr | ₹13 Cr | ₹15 Cr | ₹4 Cr | ₹0 Cr | ₹12 Cr |
| Other assets | ₹363 Cr | ₹378 Cr | ₹347 Cr | ₹293 Cr | ₹406 Cr | ₹408 Cr |
| Total assets | ₹683 Cr | ₹713 Cr | ₹664 Cr | ₹565 Cr | ₹651 Cr | ₹652 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Aug 2026
Since Sep 2025, the public trimmed −1.80 pp while others added +1.41 pp. The shareholder count grew 7% to 14,777.
- Promoters
- 64.1%
- FIIs
- 0.4%
- DIIs
- 0.0%
- Public
- 33.0%
- Others
- 2.5%
Since Sep 2025
- Public −1.80 pp
- Others +1.41 pp
- FIIs +0.35 pp
How it drifted, 12 quarters
Over this window the public fell from 36.0% to 33.0% — −3.1 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 62.1%, Public 36.0%, Others 1.9%.Mar '24: Promoters 62.1%, Public 36.0%, Others 1.9%.Jun '24: Promoters 62.1%, Public 36.1%, Others 1.8%.Sep '24: Promoters 62.1%, FIIs 0.1%, Public 36.4%, Others 1.5%.Dec '24: Promoters 62.1%, FIIs 0.0%, Public 37.0%, Others 0.9%.Mar '25: Promoters 64.1%, FIIs 0.0%, Public 35.0%, Others 0.9%.Jun '25: Promoters 64.1%, FIIs 0.0%, Public 35.0%, Others 0.9%.Sep '25: Promoters 64.1%, FIIs 0.0%, Public 34.8%, Others 1.1%.Dec '25: Promoters 64.1%, FIIs 0.0%, Public 34.0%, Others 1.9%.Mar '26: Promoters 64.1%, FIIs 0.0%, Public 33.3%, Others 2.6%.Jun '26: Promoters 64.1%, FIIs 0.1%, DIIs 0.0%, Public 33.2%, Others 2.5%.Aug '26: Promoters 64.1%, FIIs 0.4%, DIIs 0.0%, Public 33.0%, Others 2.5%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Investor Education and Protection Fund (IEPF) newly disclosed 0.60% held
- Unclaimed or Suspense or Escrow Account newly disclosed 0.16% held
- Independent Director or his relatives newly disclosed 0.02% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Aug 2026 filing
Every holder of Fermenta Biotech Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Krishna Datla | 36.04% | unchanged |
| Satish Varma Azad Nadimpally | 11.73% | unchanged |
| Anupama Datla Desai | 8.70% | unchanged |
| Preeti Thakkar | 7.61% | unchanged |
| Rakesh Kantilal Shah | 1.72% | unchanged |
| Krishan Premnarayen | 1.38% | unchanged |
| Investor Education and Protection Fund (IEPF) | 0.60% | newly disclosed |
| Unclaimed or Suspense or Escrow Account | 0.16% | newly disclosed |
| Independent Director or his relatives | 0.02% | newly disclosed |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Fermenta Biotech Limited
Guides on how to read this kind of business and the numbers that matter.